Repligen seeks European OK for MRI pancreas agent
This article was originally published in Scrip
Executive Summary
After winning a six-month priority review last month from the US FDA for SecreFlo (RG1068), a synthetic version of human secretin – with a decision expected by 21 June – Repligen has turned its eyes to the European market by submitting a marketing authorization application (MAA) for the drug as an agent to improve the detection of pancreatic duct abnormalities in patients with pancreatitis (scripintelligence, 27 February 2012).